CB12 in the news!
After the first quarter of 2014, you may have more patients ask about the effective bad breath solution that is CB12.
CB12 will be sponsoring the local weather on ITV news from the beginning of January to the end of March, in an effort to make the product top of mind for consumers who seek effective relief from chronic halitosis.
There are many scientific reasons why CB12 should be top of mind for dental professionals as well. Heading the list is its patented formula with low concentrations of zinc acetate and chlorhexidine, which have proven effective at neutralising all three Volatile Sulphur Compounds (VSCs) that cause halitosis.
Other excellent reasons for recommending the product are its long-lasting 12-hour protection,[i] and its superior performance against 18 other leading mouthwash brands.[ii] For patients looking to effectively manage bad breath, CB12 is great news.
For immediate and lasting relief from foul mouth odours, you can confidently recommend CB12.
For more information about CB12 and how it could benefit your patients, please visit www.cb12.co.uk
[i] Thrane et. al., Dental Health, Zn and CHX mouthwash is effective against VSCs responsible for halitosis for up to 12 hours, (2009) 48 (3): 8-12
[ii] Thrane et. al., The Journal of Clinical Dentistry, A new mouthrinse combining zinc and chlorhexidine in low concentrations provides superior efficacy against halitosis compared to existing formulations: A double-blind clinical study, (2007) 18 (3):82-86
About the author
Related Posts
Comments
By accepting you will be accessing a service provided by a third-party external to https://www.gdpuk.com/
GDPUK Ltd announces sale of intellectual property to leading publisher Cogora Group
GDPUK Ltd today announces the sale of its intellectual property assets to Cogora Group, one of the UK's leading publishers of healthcare brands, events and educational platforms.
The decision to sell GDPUK’s intellectual property forms part of a considered transition to ensure the long‑term stewardship and development of the brand and associated assets. Cogora brings a wealth of experience and expertise to support the continued evolution of the dentistry brand within its wide portfolio of market-leading healthcare publications. Its award-winning titles include Pulse, a long‑standing and widely recognised source of political news and clinical education for GPs, Nursing in Practice, Management in Practice, The Pharmacist, Pulse PCN and Healthcare Leader, as well as two secondary care publications – Hospital Healthcare Europe and Hospital Pharmacy Europe. The purchase will cement Cogora as the biggest publisher of primary care titles in the UK and allow it to bring its expertise in providing news, analysis, opinion and groundbreaking stories to GDPUK, as well as continue giving dentists and dental staff a voice through its website.
“After careful consideration, we believe that Cogora is well positioned to take GDPUK’s intellectual property forward,” said Tony Jacobs, founder, editor and publisher of GDPUK.com . “This transaction provides continuity for the professional community associated with GDPUK and creates opportunities for future growth under experienced ownership.”
Tony will continue involvement in GDPUK on a consulting basis.
GDPUK Ltd has worked to ensure an orderly transfer of the intellectual property and wishes Cogora every success in its future development.